Novo Nordisk A/S revenue for the last year amounted to 33.85 B USD, the most of which — 31.21 B USD — came from its highest performing source at the moment, Diabetes and Obesity Care, the year earlier bringing 22.10 B USD. The greatest contribution to the revenue figure was made by United States — last year it brought Novo Nordisk A/S 18.50 B USD, and the year before that — 11.96 B USD.